Overall, our in vivo data indicated that mast cells and neutrophils, under activation by the tumor microenvironment, demonstrate up-regulation of ANXA1/FPR2 as an anti-inflammatory response mechanism to resolve inflammation and proliferation in laryngeal cancer. This evidence concerns the gene FPR2 and laryngeal carcinoma.